# Alzinova > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/alzinova). ## Overview Alzinova AB is a Swedish biopharmaceutical company focused on developing treatments for Alzheimer’s disease. Its core programs are the therapeutic vaccine ALZ-101 and the monoclonal antibody ALZ-201, both built on the company’s proprietary scientific platform. ## Products & services • ALZ-101 therapeutic vaccine for Alzheimer’s disease • ALZ-201 monoclonal antibody program • Preclinical and clinical development services for its own pipeline • Outlicensing and partnering of drug candidates - **Therapeutic vaccine** (50%) — ALZ-101 is a vaccine candidate designed for the treatment of Alzheimer’s disease. - **Monoclonal antibody** (20%) — ALZ-201 is an antibody program intended as a complementary Alzheimer’s treatment. - **Clinical development pipeline** (20%) — Internal R&D activities that advance the company’s drug candidates through studies. - **Partnering and outlicensing** (10%) — Business development activities aimed at licensing candidates to pharma partners. - ALZ-101 therapeutic vaccine for Alzheimer’s disease - ALZ-201 monoclonal antibody program - Preclinical and clinical development of proprietary candidates - Outlicensing and partnering of drug candidates ## Customers Alzinova does not sell commercial medicines today; its direct counterparties are pharmaceutical companies, potential licensing partners, CROs, suppliers, and clinical research collaborators. The end beneficiaries are Alzheimer’s patients, while the economic buyers of the programs are larger drug developers that can fund late-stage trials, registration, and commercialization. - **Pharmaceutical partnering companies** (primary) — They buy rights to ALZ-101 or ALZ-201 through outlicensing or acquisition because they have the scale to run late-stage development and commercialization. - **Clinical research organizations** (secondary) — They provide trial execution, regulatory support, and study operations needed to advance the pipeline. - **Manufacturing and supply partners** (secondary) — They produce drug substance and drug product for preclinical and clinical use. - **Institutional investors and financing partners** (primary) — They fund the company through equity and other capital raises that support development work. - Large pharmaceutical partners seeking Alzheimer’s assets - Potential licensees evaluating ALZ-101 and ALZ-201 - CROs and trial vendors supporting clinical studies - Suppliers and manufacturers for drug substance/product - Ultimately, Alzheimer’s patients as end beneficiaries ## Geography Alzinova is headquartered in Sweden and reports in SEK, with operations centered on Swedish corporate and development activities. Its business is international in scope because clinical development, regulatory interactions, and partnering discussions involve global pharma counterparties and trial infrastructure, including references to the U.S., Europe, the U.K., and Saudi Arabia. - Sweden is the corporate base and reporting currency is SEK - Clinical and regulatory work is organized for global development - U.S. regulatory status supports partnering discussions - Europe is relevant for scientific and regulatory engagement - Saudi Arabia is mentioned as a collaboration market ## Strategy Alzinova’s strategy is to advance ALZ-101 through clinical proof-of-concept while building partnering optionality with larger pharmaceutical companies. It also continues to develop ALZ-201 as a complementary asset, using clinical and regulatory data to strengthen the platform’s licensing value. - **Advance ALZ-101 into Phase II** (short-term) — Clinical proof-of-concept is central to validating the lead asset and increasing partnering value. - **Secure strategic partnerships** (short-term) — A larger partner can fund late-stage development, registration, and commercialization. - **Build a complementary pipeline around ALZ-201** (medium-term) — A second asset can broaden the platform and create additional partnering options. - Advance ALZ-101 into Phase II clinical development - Use clinical data to support outlicensing discussions - Develop ALZ-201 as a complementary Alzheimer’s asset - Maintain parallel business development and clinical work - Leverage regulatory progress to improve partner appeal ## Risks Alzinova’s business depends on clinical success, regulatory acceptance, and the ability to finance long development cycles before any product revenue exists. The main risks are trial failure, partner dependence, manufacturing quality, key-person reliance, and the need for repeated external funding. - **Clinical development failure** [high] — ALZ-101 must show acceptable efficacy and safety in later-stage studies to justify continuation and partnering. - **Liquidity and financing dependence** [high] — The company has no commercial product revenue and relies on external capital to fund R&D and trials. - **Supplier and manufacturer dependence** [medium] — Critical development work is outsourced and quality failures could delay studies or regulatory readiness. - **Key-person and recruitment risk** [medium] — A small organization makes the company sensitive to loss of specialized scientific and regulatory staff. - ALZ-101 may fail to show sufficient efficacy in Phase II - Clinical and regulatory delays can push out partnering timelines - The company depends on external financing before commercialization - Supplier and CRO quality issues can disrupt development - Small organization creates key-person and recruitment risk ## Accounting Alzinova’s reported results are heavily shaped by capitalized development costs, since R&D for drug substance and drug product is recorded on the balance sheet rather than expensed immediately when eligible. Reported performance is also affected by equity financing, warrant programs, and going-concern considerations, while the absence of product revenue means small changes in development spend can materially change period results. - **Capitalized development costs** — Reported expenses and balance sheet intangible assets - **Clinical study and regulatory cost timing** — Quarter-to-quarter comparability - **Equity financing and warrants** — EPS, dilution, and cash runway - **Going-concern judgment** — Financial statement disclosures and investor interpretation - Capitalization of R&D affects operating expense timing - Clinical and regulatory costs drive quarterly volatility - Equity issues and warrants affect share count and dilution - Going-concern assessment is important for valuation - No product revenue means accounting is dominated by R&D --- *Last updated: 2026-08-11T04:04:50.864590+00:00*